Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: Does the pattern of recurrence differ for patients with complete response and those with partial or no response?
Received 7 July 2008; received in revised form 26 June 2009; accepted 29 July 2009.
Objective
We hypothesized that most relapses in patients with esophageal cancer having neoadjuvant chemoradiation therapy would occur outside of the surgical and radiation fields.
Methods
Recurrence patterns, time to recurrence, and median survival were examined in 267 patients who had esophagectomy after neoadjuvant chemoradiation therapy at Johns Hopkins over 19 years.
Results
Of 267 patients, 82 (30.7%) showed complete response to neoadjuvant therapy, with 108 (40.4%) and 77 (28.8%) showing partial response or no response, respectively. Recurrence developed in 84 patients (patients with complete response 18/82, 21.4%; patients with partial response 39/108, 36.1%; patients with no response 27/77, 35.1%; P = .055, respectively). Most patients had recurrences at distant sites (65/84;77.4%) regardless of pathologic response, and subsequent survival was brief (median 8.37 months). Median disease-free survival was short (10 months) and did not differ based on recurrence site for patients with partial response or no response, but was longer for patients with complete response with distant recurrence, whose median disease-free survival was 27.3 months (P = .008). By multivariate analysis, no other factor except for pathologic response to neoadjuvant therapy was associated with disease recurrence or death. Patients with partial response or no response were 1.97 and 2.23 times more likely to have recurrence than patients with complete response (P = .024 and P = .012, respectively).
Conclusions
Most esophageal cancer recurrences after neoadjuvant therapy and surgery are distant, and survival time after recurrence is short regardless of pathologic response. Fewer patients achieving complete response had recurrences, and distant recurrences in these patients manifest later than in patients showing partial response and those showing no response. Only pathologic response is significantly associated with disease recurrence, suggesting that tumor biology and chemosensitivity are critical in long-term patient outcome.
aDivision of Thoracic Surgery, Department of Surgery, Johns Hopkins School of Medicine, Baltimore, Md
bDepartment of Oncology, Johns Hopkins School of Medicine, Baltimore, Md
cDepartment of Thoracic Surgery, Union Memorial Hospital, Baltimore, Md
Address for reprints: Dr Malcolm V. Brock, Division of Thoracic Surgery, Department of Surgery, 600 North Wolfe St, Blalock 240, The Johns Hopkins Hospital, Baltimore, MD 21287.
Disclosures: R.A.M. was supported on the Ruth L. Kirschstein National Research Service Award (T32DK007713) while undertaking this study. M.V.B. was supported in part for this work by National Institutes of Health Award (NIH 1R33CA127055-01).
Presented at the annual meeting of Western Thoracic Surgical Association, Kona, Hawaii, June 25, 2008.
∗ R.A.M. and C.M.H. contributed equally to this article.
ABSTRACT